Financial Snapshot

Revenue
$52.29M
TTM
Gross Margin
Net Earnings
-$134.8M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
134.68%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$39.13M
Q3 2024
Cash
Q3 2024
P/E
-3.002
Nov 29, 2024 EST
Free Cash Flow
-$117.1M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997
Revenue $176.2M $111.3M $110.7M $118.2M $102.4M $84.45M $36.57M $19.39M $39.54M $45.87M $24.13M $21.66M $10.32M $20.80M $22.20M $16.20M $9.100M $7.900M $2.500M $1.300M $2.600M $4.300M $4.900M $3.400M $2.200M $2.000M $1.200M
YoY Change 58.34% 0.54% -6.34% 15.39% 21.29% 130.95% 88.6% -50.96% -13.8% 90.07% 11.44% 109.86% -50.39% -6.31% 37.04% 78.02% 15.19% 216.0% 92.31% -50.0% -39.53% -12.24% 44.12% 54.55% 10.0% 66.67% 100.0%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997
Revenue $176.2M $111.3M $110.7M $118.2M $102.4M $84.45M $36.57M $19.39M $39.54M $45.87M $24.13M $21.66M $10.32M $20.80M $22.20M $16.20M $9.100M $7.900M $2.500M $1.300M $2.600M $4.300M $4.900M $3.400M $2.200M $2.000M $1.200M
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997
Selling, General & Admin $57.17M $62.68M $63.22M $67.10M $61.70M $44.60M $27.20M $26.30M $19.20M $15.70M $13.70M $12.10M $14.00M $12.60M $12.60M $10.30M $6.900M $5.900M $5.300M $4.800M $3.700M $4.200M $4.800M $4.600M $1.800M $1.200M $800.0K
YoY Change -8.8% -0.85% -5.78% 8.75% 38.34% 63.97% 3.42% 36.98% 22.29% 14.6% 13.22% -13.57% 11.11% 0.0% 22.33% 49.28% 16.95% 11.32% 10.42% 29.73% -11.9% -12.5% 4.35% 155.56% 50.0% 50.0% 166.67%
% of Gross Profit
Research & Development $234.1M $249.9M $230.8M $180.6M $145.9M $114.9M $65.73M $65.60M $67.20M $56.97M $37.04M $31.71M $32.10M $33.20M $29.00M $31.20M $27.00M $22.80M $10.90M $11.20M $10.60M $13.40M $15.50M $11.30M $4.300M $4.300M $1.700M
YoY Change -6.34% 8.27% 27.77% 23.8% 27.04% 74.76% 0.2% -2.38% 17.95% 53.82% 16.81% -1.21% -3.32% 14.48% -7.05% 15.56% 18.42% 109.17% -2.68% 5.66% -20.9% -13.55% 37.17% 162.79% 0.0% 152.94% 183.33%
% of Gross Profit
Depreciation & Amortization $15.10M $12.10M $9.400M $5.700M $3.900M $2.400M $1.500M $997.0K $988.0K $549.0K $569.0K $660.0K $646.0K $700.0K $600.0K $500.0K $300.0K $200.0K $300.0K $600.0K $800.0K $1.400M $1.200M $400.0K $200.0K $100.0K $0.00
YoY Change 24.79% 28.72% 64.91% 46.15% 62.5% 60.0% 50.45% 0.91% 79.96% -3.51% -13.79% 2.17% -7.71% 16.67% 20.0% 66.67% 50.0% -33.33% -50.0% -25.0% -42.86% 16.67% 200.0% 100.0% 100.0%
% of Gross Profit
Operating Expenses $450.2M $312.6M $294.0M $247.7M $207.6M $161.6M $92.93M $91.95M $86.40M $72.65M $50.84M $43.85M $46.14M $45.70M $41.60M $41.60M $33.90M $28.60M $16.20M $16.00M $14.30M $17.50M $20.20M $15.90M $6.100M $5.500M $2.500M
YoY Change 44.04% 6.31% 18.69% 19.33% 28.47% 73.9% 1.07% 6.43% 18.92% 42.9% 15.93% -4.96% 0.96% 9.86% 0.0% 22.71% 18.53% 76.54% 1.25% 11.89% -18.29% -13.37% 27.04% 160.66% 10.91% 120.0% 150.0%
Operating Profit -$274.0M -$201.3M -$183.3M -$129.6M -$105.2M -$77.15M -$56.36M -$72.56M -$46.86M -$26.78M -$26.71M -$22.20M -$35.82M
YoY Change 36.13% 9.79% 41.52% 23.17% 36.33% 36.89% -22.32% 54.86% 74.96% 0.28% 20.31% -38.03%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997
Interest Expense $11.10M $9.432M $5.346M $8.800M $9.800M $8.300M $1.800M $900.0K $400.0K $400.0K $100.0K -$100.0K $100.0K $100.0K $500.0K $2.200M $3.200M $2.400M $900.0K $600.0K $800.0K $1.400M $3.200M $3.400M $100.0K $200.0K -$100.0K
YoY Change 17.71% 76.43% -39.25% -10.2% 18.07% 361.11% 100.0% 125.0% 0.0% 300.0% -200.0% -200.0% 0.0% -80.0% -77.27% -31.25% 33.33% 166.67% 50.0% -25.0% -42.86% -56.25% -5.88% 3300.0% -50.0% -300.0%
% of Operating Profit
Other Income/Expense, Net $887.0K $431.0K $364.0K $82.00K -$66.00K $71.00K $0.00 $300.0K -$1.200M $100.0K $500.0K -$400.0K $200.0K $600.0K $400.0K
YoY Change 105.8% 18.41% 343.9% -224.24% -192.96% -100.0% -125.0% -1300.0% -80.0% -225.0% -300.0% -66.67% 50.0%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997
Pretax Income -$262.9M -$191.8M -$178.0M -$120.8M -$95.42M -$68.89M -$54.57M -$71.67M -$46.43M -$26.42M -$26.62M -$22.30M -$35.80M -$24.90M -$18.60M -$24.30M -$21.50M -$17.90M -$13.30M -$13.80M -$10.40M -$29.80M -$25.20M -$9.100M -$3.800M -$3.300M -$1.400M
YoY Change 37.04% 7.79% 47.37% 26.58% 38.51% 26.24% -23.86% 54.38% 75.74% -0.78% 19.39% -37.71% 43.78% 33.87% -23.46% 13.02% 20.11% 34.59% -3.62% 32.69% -65.1% 18.25% 176.92% 139.47% 15.15% 135.71% 366.67%
Income Tax -$5.072M $429.0K $306.0K $345.0K $0.00 $0.00 $0.00 -$14.00K -$5.722M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$257.8M -$192.3M -$178.3M -$121.0M -$95.19M -$68.33M -$54.57M -$71.66M -$40.70M -$26.42M -$26.62M -$22.26M -$35.75M -$24.90M -$18.60M -$24.30M -$21.50M -$17.90M -$13.30M -$13.80M -$10.40M -$29.80M -$25.20M -$9.100M -$3.800M -$3.300M -$1.400M
YoY Change 34.08% 7.86% 47.35% 27.12% 39.3% 25.23% -23.85% 76.05% 54.08% -0.78% 19.58% -37.72% 43.57% 33.87% -23.46% 13.02% 20.11% 34.59% -3.62% 32.69% -65.1% 18.25% 176.92% 139.47% 15.15% 135.71% 366.67%
Net Earnings / Revenue -146.3% -172.78% -161.05% -102.37% -92.93% -80.91% -149.23% -369.58% -102.94% -57.59% -110.32% -102.81% -346.45% -119.71% -83.78% -150.0% -236.26% -226.58% -532.0% -1061.54% -400.0% -693.02% -514.29% -267.65% -172.73% -165.0% -116.67%
Basic Earnings Per Share -$1.48 -$1.25 -$1.23 -$0.90 -$0.85
Diluted Earnings Per Share -$1.48 -$1.25 -$1.23 -$0.90 -$0.85 -$704.9K -$699.1K -$1.016M -$583.1K -$394.0K -$475.0K -$423.1K -$708.9K -$550.9K -$442.9K -$595.6K -$574.9K -$550.8K -$513.5K -$549.8K -$419.4K -$1.216M -$1.091M -$523.0K -$633.3K -$569.0K -$254.5K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997
Cash & Short-Term Investments $81.00M $277.6M $376.5M $641.4M $362.5M $400.1M $243.3M $142.5M $209.0M $179.0M $92.80M $63.50M $84.10M $60.30M $84.90M $64.80M $81.10M $53.90M $47.00M $33.30M $43.90M $52.10M $61.60M $63.50M $7.500M $3.100M
YoY Change -70.82% -26.27% -41.29% 76.94% -9.4% 64.45% 70.74% -31.82% 16.76% 92.89% 46.14% -24.49% 39.47% -28.98% 31.02% -20.1% 50.46% 14.68% 41.14% -24.15% -15.74% -15.42% -2.99% 746.67% 141.94%
Cash & Equivalents $45.20M $100.4M $178.9M $131.3M $80.40M $140.4M $49.80M $22.10M $69.50M $6.000M $10.20M $21.70M $16.80M $10.80M $21.20M $19.40M $12.30M $12.70M $18.50M $8.600M $9.800M $17.60M $7.600M $10.20M $300.0K $1.300M
Short-Term Investments $35.80M $177.2M $197.7M $510.1M $282.0M $259.7M $193.5M $120.5M $139.5M $172.9M $82.60M $41.90M $67.40M $49.50M $63.80M $45.40M $68.80M $41.20M $28.40M $24.60M $34.10M $34.50M $54.00M $53.40M $7.300M $1.800M
Other Short-Term Assets $12.00M $18.22M $15.86M $12.00M $5.400M $5.300M $1.500M $1.800M $800.0K $1.100M $1.000M $500.0K $300.0K $300.0K $400.0K $300.0K $500.0K $600.0K $300.0K $300.0K $300.0K $400.0K $400.0K $300.0K $200.0K $100.0K
YoY Change -34.15% 14.91% 32.16% 122.22% 1.89% 253.33% -16.67% 125.0% -27.27% 10.0% 100.0% 66.67% 0.0% -25.0% 33.33% -40.0% -16.67% 100.0% 0.0% 0.0% -25.0% 0.0% 33.33% 50.0% 100.0%
Inventory
Prepaid Expenses
Receivables $923.0K $3.678M $6.013M $5.200M $36.90M $4.700M $3.300M $5.000M $2.500M $10.40M $3.200M $4.100M $900.0K $400.0K $100.0K $500.0K $200.0K $500.0K $1.000M $600.0K $700.0K $1.100M $800.0K $1.500M $600.0K $400.0K
Other Receivables $403.0K $794.0K $349.0K $1.100M $700.0K $300.0K $300.0K $200.0K $300.0K $400.0K $300.0K $200.0K $400.0K $300.0K $300.0K $200.0K $300.0K $0.00 $200.0K $200.0K $400.0K $400.0K $900.0K $1.200M $0.00 $0.00
Total Short-Term Assets $94.33M $300.3M $398.8M $659.7M $405.5M $410.5M $248.4M $149.6M $212.6M $190.9M $97.30M $68.40M $85.70M $61.30M $85.80M $65.90M $82.10M $55.10M $48.50M $34.40M $45.30M $54.10M $63.80M $66.50M $8.200M $3.500M
YoY Change -68.59% -24.69% -39.55% 62.69% -1.22% 65.26% 66.04% -29.63% 11.37% 96.2% 42.25% -20.19% 39.8% -28.55% 30.2% -19.73% 49.0% 13.61% 40.99% -24.06% -16.27% -15.2% -4.06% 710.98% 134.29%
Property, Plant & Equipment $52.87M $125.5M $124.7M $112.4M $107.2M $78.70M $31.10M $6.600M $2.900M $1.500M $1.400M $1.500M $1.600M $1.700M $1.700M $2.000M $1.800M $700.0K $500.0K $300.0K $900.0K $1.800M $2.800M $2.000M $600.0K $400.0K
YoY Change -57.89% 0.66% 10.95% 4.85% 36.21% 153.05% 371.21% 127.59% 93.33% 7.14% -6.67% -6.25% -5.88% 0.0% -15.0% 11.11% 157.14% 40.0% 66.67% -66.67% -50.0% -35.71% 40.0% 233.33% 50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $29.85M $88.17M $50.50M $21.80M $1.000M $47.30M $38.70M $12.60M
YoY Change -100.0% -66.15% 74.59% 131.65% 22.22% 207.14%
Other Assets $18.13M $18.52M $16.82M $15.10M $10.60M $6.200M $4.700M $200.0K $200.0K $100.0K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $300.0K $100.0K $400.0K $300.0K $100.0K
YoY Change -2.14% 10.13% 11.38% 42.45% 70.97% 31.91% 2250.0% 0.0% 100.0% -100.0% 200.0% -75.0% 33.33% 200.0%
Total Long-Term Assets $70.99M $262.2M $323.2M $278.9M $232.0M $179.9M $38.30M $8.300M $4.600M $52.30M $43.50M $14.10M $1.600M $1.700M $1.600M $2.000M $1.800M $700.0K $500.0K $300.0K $900.0K $2.100M $21.20M $2.400M $1.000M $500.0K
YoY Change -72.92% -18.87% 15.87% 20.22% 28.96% 369.71% 361.45% 80.43% -91.2% 20.23% 208.51% 781.25% -5.88% 6.25% -20.0% 11.11% 157.14% 40.0% 66.67% -66.67% -57.14% -90.09% 783.33% 140.0% 100.0%
Total Assets $165.3M $562.5M $721.9M $938.6M $637.5M $590.4M $286.7M $157.9M $217.2M $243.2M $140.8M $82.50M $87.30M $63.00M $87.40M $67.90M $83.90M $55.80M $49.00M $34.70M $46.20M $56.20M $85.00M $68.90M $9.200M $4.000M
YoY Change
Accounts Payable $15.26M $22.42M $9.759M -$6.100M $6.700M $3.400M $0.00 $2.600M $3.900M $5.500M $3.000M $3.000M $4.100M $3.500M $1.300M $1.700M $3.500M $1.700M $1.600M $900.0K $800.0K $900.0K $1.300M $600.0K $300.0K $200.0K
YoY Change -31.93% 129.72% -259.98% -191.04% 97.06% -100.0% -33.33% -29.09% 83.33% 0.0% -26.83% 17.14% 169.23% -23.53% -51.43% 105.88% 6.25% 77.78% 12.5% -11.11% -30.77% 116.67% 100.0% 50.0%
Accrued Expenses $20.74M $34.45M $30.61M $48.80M $22.00M $22.40M $14.70M $6.000M $6.700M $5.800M $4.400M $3.300M $2.900M $3.000M $2.300M $2.400M $1.200M $900.0K $900.0K $700.0K $600.0K $700.0K $700.0K $700.0K $200.0K $200.0K
YoY Change -39.79% 12.52% -37.27% 121.82% -1.79% 52.38% 145.0% -10.45% 15.52% 31.82% 33.33% 13.79% -3.33% 30.43% -4.17% 100.0% 33.33% 0.0% 28.57% 16.67% -14.29% 0.0% 0.0% 250.0% 0.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $47.73M $111.7M $127.9M $143.5M $69.90M $78.50M $44.90M $13.30M $20.10M $20.90M $10.10M $8.800M $7.200M $7.100M $15.70M $11.60M $9.700M $5.200M $6.800M $2.300M $1.600M $2.000M $2.400M $2.000M $1.000M $400.0K
YoY Change -57.27% -12.65% -10.88% 105.29% -10.96% 74.83% 237.59% -33.83% -3.83% 106.93% 14.77% 22.22% 1.41% -54.78% 35.34% 19.59% 86.54% -23.53% 195.65% 43.75% -20.0% -16.67% 20.0% 100.0% 150.0%
Long-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $24.70M $3.900M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $300.0K $0.00 $300.0K $300.0K
YoY Change -100.0% 533.33% -100.0% -100.0% 0.0%
Other Long-Term Liabilities $34.70M $149.6M $212.0M $290.5M $128.3M $137.9M $29.20M $4.500M $4.700M $14.90M $8.200M $8.800M $0.00 $800.0K $2.100M $1.900M $4.400M
YoY Change -76.8% -29.46% -27.01% 126.42% -6.96% 372.26% 548.89% -4.26% -68.46% 81.71% -6.82% -100.0% -61.9% 10.53% -56.82%
Total Long-Term Liabilities $34.70M $149.6M $212.0M $290.5M $128.3M $137.9M $53.90M $8.400M $4.700M $14.90M $8.200M $8.800M $0.00 $0.00 $0.00 $800.0K $2.100M $1.900M $4.400M $0.00 $0.00 $0.00 $300.0K $0.00 $300.0K $300.0K
YoY Change -76.8% -29.46% -27.01% 126.42% -6.96% 155.84% 541.67% 78.72% -68.46% 81.71% -6.82% -100.0% -61.9% 10.53% -56.82% -100.0% -100.0% 0.0%
Total Liabilities $82.43M $267.6M $346.6M $440.3M $205.0M $223.9M $98.80M $21.70M $24.80M $36.60M $19.10M $17.60M $7.200M $7.100M $15.70M $12.50M $11.80M $7.100M $11.20M $2.300M $1.600M $2.000M $2.700M $2.000M $1.300M $600.0K
YoY Change -69.19% -22.8% -21.29% 114.78% -8.44% 126.62% 355.3% -12.5% -32.24% 91.62% 8.52% 144.44% 1.41% -54.78% 25.6% 5.93% 66.2% -36.61% 386.96% 43.75% -20.0% -25.93% 35.0% 53.85% 116.67%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997
Basic Shares Outstanding 174.4M shares 154.3M shares 144.6M shares 134.4M shares 112.1M shares
Diluted Shares Outstanding 174.4M shares 154.3M shares 144.6M shares 134.4M shares 112.1M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $404.77 Million

About SANGAMO THERAPEUTICS, INC

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The company is headquartered in Richmond California, California and currently employs 405 full-time employees. The company went IPO on 2000-04-06. The firm's neurology preclinical development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases, and development of novel engineered adeno-associated virus (AAV) capsids to deliver its therapies to the intended neurological targets. The firm's zinc finger epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid discovery platform is expanding delivery beyond intrathecal delivery capsids, including in the central nervous system. Its clinical-stage product candidates are Isaralgagene civaparvovec, also known as ST-920, its wholly-owned gene therapy product candidate for the treatment of Fabry disease, and TX200, its wholly-owned CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation.

Industry: Biological Products, (No Diagnostic Substances) Peers: Allovir, Inc. Arcellx, Inc. Coherus BioSciences, Inc. MANNKIND CORP Mirum Pharmaceuticals, Inc. NORTHWEST BIOTHERAPEUTICS INC Viridian Therapeutics, Inc.\DE Replimune Group, Inc. Seres Therapeutics, Inc.